Revisionary jurisdiction cannot reopen share capital assessments where adequate inquiry supports a permissible view and no independent error is establ...
Reassessment jurisdiction fails where unverified portal information is aggregated without examining the taxpayer's explanation or relevance of entries...
Statutory sanction for delayed reassessment requires approval from the prescribed authority; approval by an inferior authority invalidates jurisdictio...
Transfer pricing margin adjustments require matching treatment of non-operating income and related costs, with comparability issues reconsidered on ev...
Preliminary-expense amortisation and MAT exempt-income adjustments prevailed, while trademark costs and managerial remuneration require fresh verifica...
Export valuation requires contemporaneous evidence; unrelated invoices cannot prove overvaluation, and dual penalties on firm and partner are impermis...
Ratification of resignation acceptance validates separation retrospectively, while withdrawal may be refused through reasoned administrative discretio...
An imported powdered Pelargonium sidoides root extract with maltodextrin carrier was classified as a standardized therapeutic preparation rather than a mere vegetable extract. Applying the HSN Notes and GRI 1 and 3(b), the Authority found that controlled extraction, concentration, drying and standardisation gave the goods the essential character of a medicament, intended for supply to pharmaceutical manufacturers for therapeutic or prophylactic use. It therefore ruled out Heading 1302 and Chapter 12, and classified the product under Heading 3003, specifically CTI 30039090, as a medicament not put up in measured doses or retail packing. Because the concessional customs notification applied only to Heading 1302 goods, the exemption was held unavailable.
An imported powdered Pelargonium sidoides root extract with maltodextrin carrier was classified as a standardized therapeutic preparation rather than a mere vegetable extract. Applying the HSN Notes and GRI 1 and 3(b), the Authority found that controlled extraction, concentration, drying and standardisation gave the goods the essential character of a medicament, intended for supply to pharmaceutical manufacturers for therapeutic or prophylactic use. It therefore ruled out Heading 1302 and Chapter 12, and classified the product under Heading 3003, specifically CTI 30039090, as a medicament not put up in measured doses or retail packing. Because the concessional customs notification applied only to Heading 1302 goods, the exemption was held unavailable.
Note: It is a system-generated summary and is for quick reference only.